Publicaciones en colaboración con investigadoras/es de Hospital Infanta Elena (18)

2024

  1. Correction in article by Juzga-Corrales et al. “Characteristics and outcomes of the Spanish registry for pediatric patients with bicuspid aortic valve (REVAB)”, Rev Esp Cardiol. 2023;76:961-969 (Revista Española de Cardiología (English Edition) (2024) 77(4) (358–359), (S1885585724000331), (10.1016/j.rec.2023.12.011))

    Revista Espanola de Cardiologia

  2. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Characteristics and outcomes of the Spanish registry for pediatric patients with bicuspid aortic valve (REVAB)

    Revista Espanola de Cardiologia, Vol. 76, Núm. 12, pp. 961-969

  3. Understanding the potential of digital therapies in implementing the standard of care for depression in Europe

    European Psychiatry, Vol. 66, Núm. 1

2022

  1. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Use of antihyperglycaemic therapy with cardiovascular benefit in patients with type 2 diabetes who require hospitalisation: A cross-sectional study

    Revista Clinica Espanola, Vol. 221, Núm. 9, pp. 517-528

2018

  1. Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant

    Open Forum Infectious Diseases, Vol. 5, Núm. 1

2017

  1. Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study

    Influenza and other Respiratory Viruses, Vol. 11, Núm. 2, pp. 157-164

  2. Dual Therapy with Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy with Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

    Clinical Infectious Diseases, Vol. 65, Núm. 12, pp. 2112-2118

  3. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global -clinical evaluations, serum biomarkers, genetic studies and neuroimaging- prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression

    BMC Neurology, Vol. 16, Núm. 1

  2. High Body Mass Index as a Risk Factor for Hospitalization Due to Influenza: A Case-Control Study

    Archivos de Bronconeumologia, Vol. 52, Núm. 6, pp. 299-307

  3. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

2014

  1. Predictive factors of severe multilobar pneumonia and shock in patients with influenza

    Emergency Medicine Journal, Vol. 31, Núm. 4, pp. 301-307

2013

  1. Risk factors and effectiveness of preventive measures against influenza in the community

    Influenza and other Respiratory Viruses, Vol. 7, Núm. 2, pp. 177-183

2012

  1. Effectiveness of hand hygiene and provision of information in preventing influenza cases requiring hospitalization

    Preventive Medicine, Vol. 54, Núm. 6, pp. 434-439

  2. Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: Influence of neuraminidase inhibitors

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 7, pp. 1739-1745